Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip rally offsets renewed Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices slide over 1% as US-Iran conflict clouds Hormuz reopening
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Karyopharm Reports Third Quarter 2014 Financial Results and Highlights Recent Progress
November 10, 2014 7:05 AM EST- Reported Positive Phase 1 Clinical Data Demonstrating Early Signs of Activity for Selinexor in Several Solid Tumor Settings -
- Initiated SIRTT, an Additional Registration-Directed Trial for Relapsed/Refractory Richter's Transformation -
- Provides Preview on Several Presentations and Posters at Upcoming ASH Meeting -
- Conference Call Scheduled for Today at 8:30 a.m. ET -
NEWTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third... More
Karyopharm Initiates Registration-Directed Clinical Study of Selinexor (KPT-330) in Patients With Richter's Transformation
November 10, 2014 7:00 AM ESTNEWTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced the initiation of its Phase 2 study of Selinexor (KPT-330) in patients with Richter's transformation (SIRRT) that is relapsed after or refractory to chemotherapy. This multi-center study of Selinexor, one of the company's novel, oral Selective Inhibitor of Nuclear Export / SINE compounds, will enroll approximately 50 patients in approximately 35 sites worldwide.
This single arm, open-label, Phase 2 study will evaluate the safety and efficacy of Selinexor given orally at 60 mg/m2 twice weekly. Overall response rate is the... More
